- Home
- VRNS vs CELC Comparison
VRNS vs CELC Comparison
Compare VRNS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | CELC |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VRNS | CELC |
|---|---|---|
| Price | $33.42 | $104.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | $60.68 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 2.4M | 980.5K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $608,677,000.00 | N/A |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.37 | N/A |
| 52 Week Low | $30.02 | $7.58 |
| 52 Week High | $63.90 | $112.64 |
Technical Indicators
Market Signals| Indicator | VRNS | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 61.67 |
| Support Level | $32.38 | $97.27 |
| Resistance Level | $34.05 | $112.64 |
| Average True Range (ATR) | 1.09 | 5.12 |
| MACD | 0.81 | -1.46 |
| Stochastic Oscillator | 86.60 | 34.59 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.